Unraveling the Complexity of Circulating Forms of Brain Natriuretic Peptide

Gundry, Rebekah L.; Eyk, Jennifer E. Van

doi:10.1373/clinchem.2007.086611

Cited by 11 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High specificity can minimize the incidence of false positives in device. To investigate the specificity of the drug probe-functionalized RGO-FET nanosensor for the ERα, 350 pM ERα protein and 100 nM nonspecific proteins, BSA (pI = 4.7), PARP1 (pI = 9.3), BNP (pI = 10.95), and AFP (pI = 4.9) were tested using the developed nanosensor. As shown in Figure A, the variation of Dirac point in PARP1, BSA, BNP, and AFP proteins was almost negligible, while a significant shift was found after incubation with the target ERα.…”

Section: Resultsmentioning

confidence: 99%

A Drug Molecule-Modified Graphene Field-Effect Transistor Nanosensor for Rapid, Label-Free, and Ultrasensitive Detection of Estrogen Receptor α Protein

Ming,

Li,

Yang

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

Estrogen receptor α (ERα) is an important biomarker in breast cancer diagnosis and treatment. Sensitive and accurate detection of ERα protein expression is crucial in guiding selection of an appropriate therapeutic strategy to improve the effectiveness and prognosis of breast cancer treatment. Herein, we report a liquid-gated graphene field-effect transistor (FET) biosensor that enables rapid, sensitive, and label-free detection of the ERα protein by employing a novel drug molecule as a capture probe. The drug molecule was synthesized and subsequently immobilized onto the sensing surface of the fabricated graphene FET, which was able to distinguish the ERα-positive from the ERα-negative protein. The developed sensor not only demonstrated a low detection limit (LOD: 2.62 fM) but also achieved a fast response to ERα protein samples within 30 min. Moreover, depending on the relationship between the change of dirac point and the ERα protein concentrations, the dissociation constant (K d ) was estimated to be 7.35 ± 0.06 pM, indicating that the drug probe-modified graphene FET had a good affinity with ERα protein. The nanosensor was able to analyze ERα proteins from 36 cell samples lysates. These results show that the graphene FET sensor was able to differentiate between ERα-positive and ERα-negative cells, indicating a promising biosensor for the ultrasensitive and rapid detection of ERα protein without antibody labeling.

show abstract

Section: Resultsmentioning

confidence: 99%

A Drug Molecule-Modified Graphene Field-Effect Transistor Nanosensor for Rapid, Label-Free, and Ultrasensitive Detection of Estrogen Receptor α Protein

Ming,

Li,

Yang

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

show abstract

“…Non-bioactive NT-proBNP exhibited better stability and could exist in plasma for approximately 7 days at room temperature [37]. In contrast to proBNP, BNP is not modified by glycosylation [38]. Seferian et al [39] raised antibodies against a variety of forms of BNP and found that no posttranslational modification of these peptides occurred.…”

Section: Metabolism and Forms Of Bnpmentioning

confidence: 99%

Analytical barriers in clinical B-type natriuretic peptide measurement and the promising analytical methods based on mass spectrometry technology

Xiao

et al. 2018

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

B-type natriuretic peptide (BNP) is a circulating biomarker that is mainly applied in heart failure (HF) diagnosis and to monitor disease progression. Because some identical amino acid sequences occur in the precursor and metabolites of BNP, undesirable cross-reactions are common in immunoassays. This review first summarizes current analytical methods, such as immunoassay- and mass spectrometry (MS)-based approaches, including the accuracy of measurement and the inconsistency of the results. Second, the review presents some promising approaches to resolve the current barriers in clinical BNP measurement, such as how to decrease cross-reactions and increase the measurement consistency. Specific approaches include research on novel BNP assays with higher-specificity chemical antibodies, the development of International System of Units (SI)-traceable reference materials, and the development of structure characterization methods based on state-of-the-art ambient and ion mobility MS technologies. The factors that could affect MS analysis are also discussed, such as biological sample cleanup and peptide ionization efficiency. The purpose of this review is to explore and identify the main problems in BNP clinical measurement and to present three types of approaches to resolve these problems, namely, materials, methods and instruments. Although novel approaches are proposed here, in practice, it is worth noting that the BNP-related peptides including unprocessed proBNP were all measured in clinical BNP assays. Therefore, approaches that aimed to measure a specific BNP or proBNP might be an effective way for the standardization of a particular BNP form measurement, instead of the standardization of “total” immunoreactive BNP assays in clinical at present.

show abstract

“…The detection mechanism behind the current change upon binding of target molecules for FET based amperometric biosensors can be explained by the gating effect from the surface charges introduced by the target molecules [25,26]. Because the isoelectric point (pI) of BNP used in this experiment is ~5.4 [27], the BNP molecules are negatively charged in a solution with a pH of 7.20. Therefore, the negative charges introduced by the specific binding between BNP and its receptor would lead to carrier accumulation in PANI layer, resulting in an increase in drain current [25].…”

Section: Characterization Of the 2-d Pani Layer And Testing Systemmentioning

confidence: 99%

High yield two-dimensional (2-D) polyaniline layer and its application in detection of B-type natriuretic peptide in human serum

Liu

Huang

Sanchez

et al. 2016

Sensors and Actuators B: Chemical

View full text Add to dashboard Cite

The demand for ultrasensitive and inexpensive biosensors is always strong due to increasing healthcare related concerns. Herein, we developed a simple method to prepare uniform, reliable, high yield, and low-cost two-dimensional (2-D) polyaniline layer for biosensor applications. The 2-D PANI layer's surface morphology led to a 46% increase in surface area compared to a flat 2-D surface. Due to this unique morphology and excellent semiconducting properties, the 2-D PANI layer exhibited ultrasensitive performance with excellent specificity on BNP biomarker detection in fixed Debye length condition, which is comparable to or even higher than 1-D nanostructure biosensors. In further Debye length investigation, we have observed signal changes that are varied from 8 nA to 16 nA with Debye length changes from 0.5 nm to 3.3 nm for constant BNP concentration. This result shows an improvement in device sensitivity over increasing Debye length, which conforms to Debye screening theory. With the high specificity of over 400 fold, the PANI layer was capable of monitoring significantly low BNP levels in human serum, as low as 50 pg/ml. Our findings provide an opportunity for the realization of ultrasensitive and inexpensive biosensors for clinical use.

show abstract

Unraveling the Complexity of Circulating Forms of Brain Natriuretic Peptide

Cited by 11 publications

References 15 publications

A Drug Molecule-Modified Graphene Field-Effect Transistor Nanosensor for Rapid, Label-Free, and Ultrasensitive Detection of Estrogen Receptor α Protein

A Drug Molecule-Modified Graphene Field-Effect Transistor Nanosensor for Rapid, Label-Free, and Ultrasensitive Detection of Estrogen Receptor α Protein

Analytical barriers in clinical B-type natriuretic peptide measurement and the promising analytical methods based on mass spectrometry technology

High yield two-dimensional (2-D) polyaniline layer and its application in detection of B-type natriuretic peptide in human serum

Contact Info

Product

Resources

About